ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PLSE / forecast
NVST (46) IRTC (47) ICUI (56) ATRC (63) ⌘ Pro Terminal →

Pulse Biosciences Inc (PLSE) 12-Month Stock Forecast & Price Target Cone

$52.90 +1.26% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $52.92

Pulse Biosciences Inc (PLSE) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $3.73B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PLSE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PLSE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Pulse Biosciences Inc (NASDAQ: PLSE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $52.90 (+1.26% 1D, market cap $3.73B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PLSE ranks #479 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PLSE compare to NVST and IRTC in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), PLSE carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -30.7%. By comparison, NVST (Envista Holdings Corporation) holds a D grade (46/100 RQD, P/E 84.1x, ROIC 5.1%, cap $3.78B) and IRTC (iRhythm Holdings Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -13.5%, cap $4.07B). Among the 5-stock peer group, NVST leads on earnings multiple (84.1x) while NVST leads on capital efficiency (5.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PLSE?
▼

Per PLSE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001625101), Pulse Biosciences Inc generated $350.0K in revenue (-99.8% YoY), -$72.8M in net income, and -$54.4M in free cash flow against $94.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $52.92 (+0.04%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510039
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-
Cash (6)Whales (14)SEC (8)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-8.5% Base Target
$62 Bull$48 Base$38 Bear
📬 FREE PLSE RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PLSE)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (39/100 Composite)
🔍 WHY PLSE SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (36% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (21% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
31
Grade E$48.54+4.7% Next Q
Q2 (-2Q)
34
Grade E$50.84+4.6% Next Q
Q3 (-1Q)
36
Grade E$53.20-0.6% Next Q
Current
39
Grade D-$52.90-7.6% Hist 90D α
Trajectory: E (31) → D- (39)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PLSE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PLSE currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($51.24) and Max Pain ($55.55) forces dealer call-delta covering toward $61.84.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PLSE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PLSE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 39%NO 61%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your PLSE Position Size: $10,000

Shares at $52.90: 189.0 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $37.74
$7,134
$-2,866 (-28.7%)
12M Consensus BaseTarget $48.38
$9,146
$-854 (-8.5%)
12M Bull Case BreakoutTarget $61.84
$11,690
+$1,690 (+16.9%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$5074%A
Goldman SachsSector Coverage LeadUNDERPERFORM$5869%B
JP MorganUS Large-Cap ResearchSELL$4358%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PLSE)

  • ✓Walkthrough of PLSE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PLSE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +164.10%▲ ASCENDING CHANNEL
2026-11-03O $55.48H $55.48L $52.24C $52.90VOL 466.5K
RES: $76.85SUP: $46.66SMA50: $51.24SMA200: $31.75
$61.82$49.73$37.64$25.55$13.46RES $76.85SUP $46.66$52.902026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PLSE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PLSE Butterfly Map → + Track PLSE →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -99.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PLSE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PLSE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PLSE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PLSE)

Health Care Rank #479 of 1015 ⚔️ NVST vs PLSE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PLSE vs. NVST, IRTC, ICUI, ATRC)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Pulse Biosciences Inc (PLSE) ranks #479 by composite RQD confidence (39/100, grade D-) and #186 by equity capitalization ($3.73B). Within this direct 5-issuer industry benchmark cohort, NVST leads on earnings valuation at 84.1x trailing P/E, while NVST leads on capital efficiency and profitability with 5.1% ROIC and 54.7% gross margin. ATRC currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with PLSE at 39/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PLSE ACTIVE
Pulse Biosciences Inc
D- 39/100 — -30.0% -30.7% +1.26% $3.73B Benchmark Subject
NVST
Envista Holdings Corporation
D 46/100 84.1x 54.7% 5.1% +5.10% $3.78B /nvst-vs-plse →
IRTC
iRhythm Holdings Inc.
D 47/100 — 70.6% -13.5% +2.27% $4.07B /irtc-vs-plse →
ICUI
ICU Medical Inc.
D+ 56/100 — 36.8% 1.0% -0.85% $4.10B /icui-vs-plse →
ATRC
AtriCure Inc.
C 63/100 — 75.0% -1.9% -2.24% $3.12B /atrc-vs-plse →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001625101 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pulse Biosciences Inc (PLSE) reported GAAP revenue of $350.0K (-99.8% vs. FY2024 revenue of $157.5M , and -99.7% cumulative change since FY2023) , GAAP net income of -$72.8M, operating cash flow of -$54.1M, and free cash flow of -$54.4M (-49.3% YoY). On the balance sheet, PLSE closed FY2025 with $94.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $350.0K -$72.8M -$54.1M -$54.4M $94.5M —
FY2024 (FY) 2024-12-31 $157.5M -$53.6M -$36.3M -$36.5M $132.5M —
FY2023 (FY) 2023-12-31 $122.0M -$42.2M -$33.0M -$33.0M — —

3. PLSE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PLSE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Pulse Biosciences Inc (NASDAQ: PLSE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $52.90 (+1.26% 1D, market cap $3.73B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PLSE ranks #479 in composite RQD confidence.

How does PLSE compare to NVST and IRTC in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), PLSE carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -30.7%. By comparison, NVST (Envista Holdings Corporation) holds a D grade (46/100 RQD, P/E 84.1x, ROIC 5.1%, cap $3.78B) and IRTC (iRhythm Holdings Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -13.5%, cap $4.07B). Among the 5-stock peer group, NVST leads on earnings multiple (84.1x) while NVST leads on capital efficiency (5.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PLSE?

Per PLSE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001625101), Pulse Biosciences Inc generated $350.0K in revenue (-99.8% YoY), -$72.8M in net income, and -$54.4M in free cash flow against $94.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PLSE trading relative to its 50-day, 200-day, and 52-week technical levels?

PLSE last traded at $52.90 (+1.26% on volume of 250,456 shares), positioning the stock +3.24% above its 50-day simple moving average ($51.24) and +66.61% above its 200-day simple moving average ($31.75). Across its 52-week range of $12.56 to $58.90, PLSE sits at the 87.1% percentile with a 14-day RSI of 51.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($46.29 to $59.51).

Direct Sub-Reports: PLSE RQD Cockpit PLSE 12M Forecast PLSE Earnings & Move PLSE Dividends & DRIP PLSE Insiders & 13F PLSE Whale Options PLSE Profit Sankey PLSE News & Why
ROARABLE RATING BRIEF • RQD 39/100 (D-) ✓ SEC XBRL & RQD VERIFIED

PLSE — Pulse Biosciences Inc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Pulse Biosciences Inc (PLSE) earns a live Roarable RQD composite score of 39/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $52.90 (+1.26% 1D, market capitalization $3.73B).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -30.7%, gross margin of -30.0%, operating margin of -60.0%, and free cash flow yield of -1.38%.
  • Whale 13F & Options Flow (14/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Pulse Biosciences Inc (PLSE) is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry.3M for FY 2025 . Its sector and industry classification places it within medical instrument manufacturing.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Pulse Biosciences Inc (PLSE) reported $350.0K in annual revenue (up from $157.5M in FY2024, -99.8% YoY) and -$72.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($122.0M revenue, -$42.2M net income) through FY2025, PLSE scaled operating cash flow to -$54.1M and free cash flow to -$54.4M, backed by $94.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 39/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -1.38% and institutional whale pillar of 14/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 14/20, sustained execution supports upside toward the upper end of the $12.56 – $58.90 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), PLSE carries a macro regime beta of 1.00 and gross margin of -30.0%.

  • Key Question #1: Can PLSE sustain or expand its -60.0% operating margin and -30.7% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $350.0K and free cash flow of -$54.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PLSE's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PLSE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Pulse Biosciences Inc (PLSE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PLSE Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PLSE Bull vs. Bear Conversation Board — What's Your Call at $52.90?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PLSE 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PLSE:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $68.43 (+31.0%)
📌 Pinned Debate

Institutional accumulation and options positioning score 16 / 20, the strongest pillar, with a 52-week high of $58.9 and a price of 55.

Don't sleep on PLSE's setup in Health Care. Institutional accumulation and options positioning score 16 / 20, the strongest pillar, with a 52-week high of $58.9 and a price of 55.48 after a 3.37% gain.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (39/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@ShortSeller_Dan Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (-30.0%) holds, EPS grows into the multiple faster than bears think.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $42.84 (-18.0%)
Spot @ $52.24

ROIC of -30.7%, FCF of -$54.4M in FY 2025, and cash down to $80.7M from $118.0M leave the company with weak cash generation and limited

Here is the bear case nobody on the bull side wants to address on PLSE: ROIC of -30.7%, FCF of -$54.4M in FY 2025, and cash down to $80.7M from $118.0M leave the company with weak cash generation and limited balance-sheet resilience.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%